Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China NT Pharma Group Co., Ltd. ( (HK:1011) ) has issued an announcement.
China NT Pharma Group has completed a major acquisition, taking indirect control of 58.11% of Zhejiang Kangyuan Medical Device and integrating its AI X-ray bone density systems, portable AI X-ray devices, patents, and source codes into the group’s portfolio. The deal marks a key step in the company’s shift toward an AI-driven health management platform, and small-batch deliveries of the portable AI X-ray device to customers have already begun, underscoring early commercialisation progress.
Alongside its operational pivot, the group continues to tackle its capital structure and auditor’s going-concern disclaimer by negotiating remaining debt restructuring with major creditors, including possible extensions, debt-to-equity conversions, and covenant waivers. After terminating a planned convertible bond issue in February 2026, the company is actively pursuing alternative structured financing and strategic investments from existing shareholders and new investors in the medical and health technology sector, though no definitive agreements have yet been reached, prompting a continued note of caution for shareholders and potential investors.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is a Hong Kong-listed healthcare company undergoing a strategic transformation toward an artificial intelligence-based health management platform spanning testing, treatment, and rehabilitation. Through recently acquired subsidiaries, it now indirectly controls a majority stake in Zhejiang Kangyuan Medical Device, strengthening its position in AI-powered bone health diagnostics and medical imaging.
Average Trading Volume: 251,362
Technical Sentiment Signal: Sell
Current Market Cap: HK$635.8M
Learn more about 1011 stock on TipRanks’ Stock Analysis page.